Live Energy Minerals Corp

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 9.7K

Market Cap: -

Website

Introduction: Garrett Motion, Inc. provides automobile technology. The firm engages in the design, manufacture, and sale of engineered turbocharger, electric motor technologies for original equipment manufacturers and distributors within the mobility and industrial space. It offers light vehicle gasoline, light vehicle diesel, and commercial vehicle turbochargers. The com...

Clinical Trials

Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence

Phase 2

Withdrawn

Conditions: Stress Urinary Incontinence

Interventions: Drug: GTx-024

First Posted Date: 2018-06-25

Last Posted Date: 2024-03-01

Lead Sponsor: GTx

Registration Number: NCT03566290

Locations: 🇺🇸
Clinical Research Prime, Idaho Falls, Idaho, United States
🇺🇸
William Beaumont Hospital Urology Research, Royal Oak, Michigan, United States
🇺🇸
Aventiv Research, Columbus, Ohio, United States

and more 43 locations

Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary Incontinence

Phase 2

Withdrawn

Conditions: Stress Urinary Incontinence

Interventions: Drug: Matching Placebo
Drug: GTx-024

First Posted Date: 2018-04-26

Last Posted Date: 2023-09-14

Lead Sponsor: GTx

Registration Number: NCT03508648

Locations: 🇺🇸
Urology Associates Research, Englewood, Colorado, United States
🇺🇸
Regional Urology, Shreveport, Louisiana, United States
🇺🇸
Beyer Research, Kalamazoo, Michigan, United States

and more 43 locations

Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence

Phase 2

Completed

Conditions: Stress Urinary Incontinence

Interventions: Drug: GTx 024
Drug: Placebo

First Posted Date: 2017-08-07

Last Posted Date: 2021-03-24

Lead Sponsor: GTx

Target Recruit Count: 491

Registration Number: NCT03241342

Locations: 🇺🇸
William Beaumont Hospital Urology Research, Royal Oak, Michigan, United States
🇺🇸
Circuit Clinical, West Seneca, New York, United States
🇺🇸
Alliance Urology Specialist PA, Greensboro, North Carolina, United States

and more 59 locations

Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass

Phase 2

Withdrawn

Conditions: ER+ and AR+ Breast Cancer

Interventions: Drug: GTx-024 9 or 18 mg

First Posted Date: 2016-04-21

Last Posted Date: 2024-02-26

Lead Sponsor: GTx

Registration Number: NCT02746328

Locations: 🇺🇸
University of Washington, School of Medicine, Seattle, Washington, United States

GTx-024 as a Treatment for Stress Urinary Incontinence in Women

Phase 2

Completed

Conditions: Stress Urinary Incontinence

Interventions: Drug: GTx-024

First Posted Date: 2016-01-18

Last Posted Date: 2021-02-01

Lead Sponsor: GTx

Target Recruit Count: 19

Registration Number: NCT02658448

Locations: 🇺🇸
Penn Center for Continence and Pelvic Health, University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States
🇺🇸
Urologic Consultants of Southeastern Pennsylvania, Bala-Cynwyd, Pennsylvania, United States

Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer

Phase 2

Completed

Conditions: ER+ and AR+ Breast Cancer

Interventions: Drug: GTx-024

First Posted Date: 2015-06-04

Last Posted Date: 2020-12-09

Lead Sponsor: GTx

Target Recruit Count: 136

Registration Number: NCT02463032

Locations: 🇺🇸
Holy Cross Hospital, Fort Lauderdale, Florida, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
The West Clinic, PC, Memphis, Tennessee, United States

and more 1 locations

Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

Phase 2

Terminated

Conditions: Triple Negative Breast Cancer

Interventions: Drug: GTx-024

First Posted Date: 2015-02-23

Last Posted Date: 2020-11-18

Lead Sponsor: GTx

Target Recruit Count: 32

Registration Number: NCT02368691

Locations: 🇺🇸
Holy Cross Hospital, Fort Lauderdale, Florida, United States
🇺🇸
US Oncology / Texas Oncology, P.A., Houston, Texas, United States
🇺🇸
Lakeland Regional Health Care/Cancer Center, Lakeland, Florida, United States

and more 4 locations

Phase II Study of GTx024 in Women With Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: GTx-024 9mg

First Posted Date: 2012-06-12

Last Posted Date: 2024-03-08

Lead Sponsor: GTx

Target Recruit Count: 22

Registration Number: NCT01616758

Locations: 🇺🇸
Commonwealth Hematology-Oncology, Lawrence, Massachusetts, United States
🇺🇸
Illinois Cancer Care, PC, Peoria, Illinois, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: GTx-758 125 mg
Drug: GTx-758 250 mg

First Posted Date: 2012-06-08

Last Posted Date: 2021-03-24

Lead Sponsor: GTx

Target Recruit Count: 77

Registration Number: NCT01615120

Locations: 🇺🇸
Urology Associates Medical Group, Burbank, California, United States
🇺🇸
Urology Specialists of So. California, Torrance, California, United States
🇺🇸
AMP of NY, Syracuse, New York, United States

and more 22 locations

GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: GTx-758

First Posted Date: 2011-08-22

Last Posted Date: 2023-10-06

Lead Sponsor: GTx

Target Recruit Count: 18

Registration Number: NCT01420861

Locations: 🇺🇸
GTx Investigative Site, Virginia Beach, Virginia, United States
🇺🇸
GTx Investigational Site, Jeffersonville, Indiana, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy